The role of bile acids in metabolic regulation

Journal of Endocrinology

Volumn 228, Issue 3, 2016, Pages R85-R96

  Vítek, Libor ^a   Haluzík, Martin ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Bariatric surgery; Bile acids; Diabetes; Energy homeostasis; Obesity

Indexed keywords

BILE ACID; CELL NUCLEUS RECEPTOR; GLUCOSE; INCRETIN; CELL RECEPTOR; FARNESOID X-ACTIVATED RECEPTOR; G PROTEIN COUPLED RECEPTOR; GPBAR1 PROTEIN, HUMAN;

BARIATRIC SURGERY; BILE ACID METABOLISM; CONSTIPATION; CORRELATION ANALYSIS; DIABETES MELLITUS; ENERGY EXPENDITURE; ENERGY METABOLISM; GLUCOSE HOMEOSTASIS; HUMAN; INTESTINE FLORA; METABOLIC DISORDER; METABOLIC REGULATION; NONHUMAN; OBESITY; PRIORITY JOURNAL; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION; THYROID FUNCTION; HOMEOSTASIS; LIPID METABOLISM; METABOLISM; PHYSIOLOGY; THYROID GLAND;

BARIATRIC SURGERY; BILE ACIDS AND SALTS; CONSTIPATION; DIABETES MELLITUS; ENERGY METABOLISM; GASTROINTESTINAL MICROBIOME; GLUCOSE; HOMEOSTASIS; HUMANS; INCRETINS; LIPID METABOLISM; METABOLIC DISEASES; METABOLISM; OBESITY; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECEPTORS, G-PROTEIN-COUPLED; THYROID GLAND;

EID: 84975784398     PISSN: 00220795     EISSN: 14796805     Source Type: Journal    
DOI: 10.1530/JOE-15-0469     Document Type: Review

References (141)

1. Abrahamsson H, Ostlund-Lindqvist AM, Nilsson R, SimrenM& Gillberg PG 2008 Altered bile acid metabolism in patients with constipationpredominant irritable bowel syndrome and functional constipation. Scandinavian Journal of Gastroenterology 43 1483-1488. (doi:10.1080/00365520802321212)
2. Alswat KA 2015 Role of cholestyramine in refractory hyperthyroidism: a case report and literature review. American Journal of Case Reports 16 486-490. (doi:10.12659/AJCR.893821)
3. Ashrafian H, Bueter M, Ahmed K, Suliman A, Bloom SR, Darzi A & Athanasiou T 2010 Metabolic surgery: an evolution through bariatric animal models. Obesity Reviews 11 907-920. (doi:10.1111/j.1467-789X. 2009.00701.x)
4. Backhed F, Ding H, Wang T, Hooper LV, Koh GY, Nagy A, Semenkovich CF & Gordon JI 2004 The gut microbiota as an environmental factor that regulates fat storage. PNAS 101 15718-15723. (doi:10.1073/pnas. 0407076101)
5. Begley M, Gahan CG & Hill C 2005 The interaction between bacteria and bile. FEMS Microbiology Reviews 29 625-651. (doi:10.1016/j.femsre. 2004.09.003)
6. Benhamed F, Filhoulaud G, Caron S, Lefebvre P, Staels B & Postic C 2014 O-GlcNAcylation links ChREBP and FXR to glucose-sensing. Frontiers in Endocrinology 5 230. (doi:10.3389/fendo.2014.00230)
7. Benter IF, Sarkhou F, Al-Khaldi AT, Chandrasekhar B, Attur S, Dhaunsi GS, Yousif MH & Akhtar S 2015 The dual targeting of EGFR and ErbB2 with the inhibitor Lapatinib corrects high glucose-induced apoptosis and vascular dysfunction by opposing multiple diabetes-induced signaling changes. Journal of Drug Targeting 23 506-518. (doi:10.3109/1061186X. 2015.1057150)
8. Bishop-Bailey D, Walsh DT & Warner TD 2004 Expression and activation of the farnesoid X receptor in the vasculature. PNAS 101 3668-3673. (doi:10.1073/pnas.0400046101)
9. Brasacchio D, Okabe J, Tikellis C, Balcerczyk A, George P, Baker EK, Calkin AC, Brownlee M, Cooper ME & El-Osta A 2009 Hyperglycemia induces a dynamic cooperativity of histone methylase and demethylase enzymes associated with gene-activating epigenetic marks that coexist on the lysine tail. Diabetes 58 1229-1236. (doi:10.2337/db08-1666)
10. Brufau G, Bahr MJ, Staels B, Claudel T, Ockenga J, Boker KH, Murphy EJ, Prado K, Stellaard F, Manns MP et al. 2010 Plasma bile acids are not associated with energy metabolism in humans. Nutrition and Metabolism 7 73. (doi:10.1186/1743-7075-7-73)
11. Carter D, Howlett HC, Wiernsperger NF & Bailey CJ 2003 Differential effects of metformin on bile salt absorption from the jejunum and ileum. Diabetes, Obesity and Metabolism 5 120-125. (doi:10.1046/j.1463-1326. 2003.00252.x)
12. Castro RE, Ferreira DM, Afonso MB, Borralho PM, Machado MV, Cortez-Pinto H & Rodrigues CM2013 miR-34a/SIRT1/p53 is suppressed by ursodeoxycholic acid in the rat liver and activated by disease severity in human non-alcoholic fatty liver disease. Journal of Hepatology 58 119-125. (doi:10.1016/j.jhep.2012.08.008)
13. Charach G, Rabinovich PD, Konikoff FM, Grosskopf I, Weintraub MS & Gilat T 1998 Decreased fecal bile acid output in patients with coronary atherosclerosis. Journal of Medicine 29 125-136.
14. Charach G, Grosskopf I, Rabinovich A, Shochat M, Weintraub M & Rabinovich P 2011 The association of bile acid excretion and atherosclerotic coronary artery disease. Therapeutic Advances in Gastroenterology 4 95-101. (doi:10.1177/1756283X10388682)
15. Chiang JY 2009 Bile acids: regulation of synthesis. Journal of Lipid Research 50 1955-1966. (doi:10.1194/jlr.R900010-JLR200)
16. Chow EC, Magomedova L, Quach HP, Patel R, Durk MR, Fan J, Maeng HJ, Irondi K, Anakk S, Moore DD et al. 2014 Vitamin D receptor activation down-regulates the small heterodimer partner and increases CYP7A1 to lower cholesterol. Gastroenterology 146 1048-1059. (doi:10.1053/j.gastro.2013.12.027)
17. Cipriani S, Mencarelli A, Palladino G & Fiorucci S 2010 FXR activation reverses insulin resistance and lipid abnormalities and protects against liver steatosis in Zucker (fa/fa) obese rats. Journal of Lipid Research 51 771-784. (doi:10.1194/jlr.M001602)
18. Cotillard A, Kennedy SP, Kong LC, Prifti E, Pons N, Le Chatelier E, Almeida M, Quinquis B, Levenez F, Galleron N et al. 2013 Dietary intervention impact on gut microbial gene richness. Nature 500 585-588. (doi:10.1038/nature12480)
19. Desai MS, Shabier Z, Taylor M, Lam F, Thevananther S, Kosters A & Karpen SJ 2010 Hypertrophic cardiomyopathy and dysregulation of cardiac energetics in a mouse model of biliary fibrosis. Hepatology 51 2097-2107. (doi:10.1002/hep.23585)
20. Devkota S, Wang Y, Musch MW, Leone V, Fehlner-Peach H, Nadimpalli A, Antonopoulos DA, Jabri B & Chang EB 2012 Dietary-fat-induced taurocholic acid promotes pathobiont expansion and colitis in Il10K/K mice. Nature 487 104-108. (doi:10.1038/nature11225)
21. Dixon JB, le Roux CW, Rubino F & Zimmet P 2012 Bariatric surgery for type 2 diabetes. Lancet 379 2300-2311. (doi:10.1016/S0140-6736 (12)60401-2)
22. Doignon I, Julien B, Serriere-Lanneau V, Garcin I, Alonso G, Nicou A, Monnet F, Gigou M, Humbert L, Rainteau D et al. 2011 Immediate neuroendocrine signaling after partial hepatectomy through acute portal hyperpressure and cholestasis. Journal of Hepatology 54 481-488. (doi:10.1016/j.jhep.2010.07.012)
23. Dopico AM, Walsh JV Jr & Singer JJ 2002 Natural bile acids and synthetic analogues modulate large conductance Ca2C-activated KC (BKCa) channel activity in smooth muscle cells. Journal of General Physiology 119 251-273. (doi:10.1085/jgp.20028537)
24. Duboc H, Tache Y & Hofmann AF 2014 The bile acid TGR5 membrane receptor: from basic research to clinical application. Digestive and Liver Disease 46 302-312. (doi:10.1016/j.dld.2013.10.021)
25. Duckworth PF, Vlahcevic ZR, Studer EJ, Gurley EC, Heuman DM, Beg ZH & Hylemon PB 1991 Effect of hydrophobic bile acids on 3-hydroxy-3-methylglutaryl-coenzyme A reductase activity and mRNA levels in the rat. Journal of Biochemical Chemistry 266 9413-9418.
26. Ellis EC 2006 Suppression of bile acid synthesis by thyroid hormone in primary human hepatocytes. World Journal of Gastroenterology 12 4640-4645. (doi:10.3748/wjg.v12.i29.4640)
27. Fernandes J, Su W, Rahat-Rozenbloom S, Wolever TM & Comelli EM 2014 Adiposity, gut microbiota and faecal short chain fatty acids are linked in adult humans. Nutrition & Diabetes 4 e121. (doi:10.1038/nutd. 2014.23)
28. Ferreira DF, Fiamoncini J, Prist IH, Ariga SK, de Souza HP & de Lima TM 2015 Novel role of TLR4 in NAFLD development: modulation of metabolic enzymes expression. Biochimica Biophysica Acta 1851 1353-1359. (doi:10.1016/j.bbalip.2015.07.002)
29. Fuchs C, Claudel T & Trauner M 2013 Bile acid-mediated control of liver triglycerides. Seminars in Liver Disease 33 330-342. (doi:10.1055/s-0033-1358520)
30. Furet JP, Kong LC, Tap J, Poitou C, Basdevant A, Bouillot JL, Mariat D, Corthier G, Dore J, Henegar C et al. 2010 Differential adaptation of human gut microbiota to bariatric surgery-induced weight loss: links with metabolic and low-grade inflammation markers. Diabetes 59 3049-3057. (doi:10.2337/db10-0253)
31. Gao J & Xie W 2012 Targeting xenobiotic receptors PXR and CAR for metabolic diseases. Trends in Pharmacological Sciences 33 552-558. (doi:10.1016/j.tips.2012.07.003)
32. Gao J, He J, Zhai Y, Wada T & Xie W 2009 The constitutive androstane receptor is an anti-obesity nuclear receptor that improves insulin sensitivity. Journal of Biochemical Chemistry 284 25984-25992. (doi:10.1074/jbc.M109.016808)
33. Gregor MF & Hotamisligil GS 2011 Inflammatory mechanisms in obesity. Annual Review of Immunology 29 415-445. (doi:10.1146/annurevimmunol-031210-101322)
34. Habegger KM, Al-Massadi O, Heppner KM, Myronovych A, Holland J, Berger J, Yi CX, Gao Y, Lehti M, Ottaway N et al. 2014 Duodenal nutrient exclusion improves metabolic syndrome and stimulates villus hyperplasia. Gut 63 1238-1246. (doi:10.1136/gutjnl-2013-304583)
35. Hagag P, Nissenbaum H & WeissM1998 Role of colestipol in the treatment of hyperthyroidism. Journal of Endocrinological Investigation 21 725-731. (doi:10.1007/BF03348036)
36. Haluzikova D, Lacinova Z, Kavalkova P, Drapalova J, Krizova J, Bartlova M, Mraz M, Petr T, Vitek L, Kasalicky M et al. 2013 Laparoscopic sleeve gastrectomy differentially affects serum concentrations of FGF-19 and FGF-21 in morbidly obese subjects. Obesity 21 1335-1342. (doi:10.1002/oby.20208)
37. Harach T, Pols TW, Nomura M, Maida A, Watanabe M, Auwerx J & Schoonjans K 2012 TGR5 potentiates GLP-1 secretion in response to anionic exchange resins. Scientific Reports 2 430. (doi:10.1038/srep00430)
38. Hauge-Evans AC, Reers C, Kerby A, Franklin Z, Amisten S, King AJ, Hassan Z, Vilches-Flores A, Tippu Z, Persaud SJ et al. 2014 Effect of hyperglycaemia on muscarinic M3 receptor expression and secretory sensitivity to cholinergic receptor activation in islets. Diabetes, Obesity and Metabolism 16 947-956. (doi:10.1111/dom.12301)
39. Hofmann AF 1984 Chemistry and enterohepatic circulation of bile acids. Hepatology 4 4S-14S. (doi:10.1002/hep.1840040803)
40. Hofmann AF & Eckmann L 2006 How bile acids confer gut mucosal protection against bacteria. PNAS 103 4333-4334. (doi:10.1073/pnas. 0600780103)
41. Hofmann AF, Loening-Baucke V, Lavine JE, Hagey LR, Steinbach JH, Packard CA, Griffin TL & Chatfield DA 2008 Altered bile acid metabolism in childhood functional constipation: inactivation of secretory bile acids by sulfation in a subset of patients. Journal of Pediatric Gastroenterology and Nutrition 47 598-606. (doi:10.1097/MPG. 0b013e31816920a6)
42. Holst JJ & Gromada J 2004 Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans. American Journal of Physiology-Endocrinology and Metabolism 287 E199-E206. (doi:10.1152/ajpendo.00545.2003)
43. Holst JJ, Deacon CF, Vilsboll T, Krarup T & Madsbad S 2008 Glucagon-like peptide-1, glucose homeostasis and diabetes. Trends in Molecular Medicine 14 161-168. (doi:10.1016/j.molmed.2008.01.003)
44. Holt JA, Luo G, Billin AN, Bisi J, McNeill YY, Kozarsky KF, Donahee M, Wang DY, Mansfield TA, Kliewer SA et al. 2003 Definition of a novel growth factor-dependent signal cascade for the suppression of bile acid biosynthesis. Genes and Development 17 1581-1591. (doi:10.1101/gad. 1083503)
45. Houten SM, Watanabe M & Auwerx J 2006 Endocrine functions of bile acids. EMBO Journal 25 1419-1425. (doi:10.1038/sj.emboj.7601049)
46. Huang W, Ma K, Zhang J, QatananiM, Cuvillier J, Liu J, Dong B, Huang X & Moore DD 2006 Nuclear receptor-dependent bile acid signaling is required for normal liver regeneration. Science 312 233-236. (doi:10.1126/science.1121435)
47. Hylemon PB, Zhou H, Pandak WM, Ren S, Gil G & Dent P 2009 Bile acids as regulatory molecules. Journal of Lipid Research 50 1509-1520. (doi:10.1194/jlr.R900007-JLR200)
48. Inagaki T, Moschetta A, Lee YK, Peng L, Zhao G, Downes M, Yu RT, Shelton JM, Richardson JA, Repa JJ et al. 2006 Regulation of antibacterial defense in the small intestine by the nuclear bile acid receptor. PNAS 103 3920-3925. (doi:10.1073/pnas.0509592103)
49. Islam KB, Fukiya S, HagioM, Fujii N, Ishizuka S, Ooka T, Ogura Y, Hayashi T & Yokota A 2011 Bile acid is a host factor that regulates the composition of the cecal microbiota in rats. Gastroenterology 141 1773-1781. (doi:10.1053/j.gastro.2011.07.046)
50. Jia L, Vianna CR, Fukuda M, Berglund ED, Liu C, Tao C, Sun K, Liu T, Harper MJ, Lee CE et al. 2014 Hepatocyte Toll-like receptor 4 regulates obesity-induced inflammation and insulin resistance. Nature Communications 5 3878. (doi:10.1038/ncomms4878)
51. Jiang C, Xie C, Li F, Zhang L, Nichols RG, Krausz KW, Cai J, Qi Y, Fang ZZ, Takahashi S et al. 2015 Intestinal farnesoid X receptor signaling promotes nonalcoholic fatty liver disease. Journal of Clinical Invesigation 125 386-402. (doi:10.1172/JCI76738)
52. Kaykhaei MA, Shams M, Sadegholvad A, Dabbaghmanesh MH & Omrani GR 2008 Low doses of cholestyramine in the treatment of hyperthyroidism. Endocrine 34 52-55. (doi:10.1007/s12020-008-9107-5)
53. Kemper JK 2011 Regulation of FXR transcriptional activity in health and disease: emerging roles of FXR cofactors and post-translational modifications. Biochimica Biophysica Acta 1812 842-850. (doi:10.1016/j.bbadis.2010.11.011)
54. Kharitonenkov A, Shiyanova TL, Koester A, Ford AM, Micanovic R, Galbreath EJ, Sandusky GE, Hammond LJ, Moyers JS, Owens RA et al. 2005 FGF-21 as a novel metabolic regulator. Journal of Clinical Invesigation 115 1627-1635. (doi:10.1172/JCI23606)
55. Khurana S, Raufman JP & Pallone TL 2011 Bile acids regulate cardiovascular function. Clinical and Translational Science 4 210-218. (doi:10.1111/j.1752-8062.2011.00272.x)
56. Kim YC, Fang S, Byun S, Seok S, Kemper B & Kemper JK 2015 Farnesoid X receptor-induced lysine-specific histone demethylase reduces hepatic bile acid levels and protects the liver against bile acid toxicity. Hepatology 62 220-231. (doi:10.1002/hep.27677)
57. Kitada M & Koya D 2013 SIRT1 in type 2 diabetes: mechanisms and therapeutic potential. Diabetes & Metabolism Journal 37 315-325. (doi:10.4093/dmj.2013.37.5.315)
58. Kocsar LT, Bertok L & Varteresz V 1969 Effect of bile acids on the intestinal absorption of endotoxin in rats. Journal of Bacteriology 100 220-223.
59. Kohli R, Kirby M, Setchell KD, Jha P, Klustaitis K, Woollett LA, Pfluger PT, Balistreri WF, Tso P, Jandacek RJ et al. 2010 Intestinal adaptation after ileal interposition surgery increases bile acid recycling and protects against obesity-related comorbidities. American Journal of Physiology-Gastrointestinal and Liver Physiology 299 G652-G660. (doi:10.1152/ajpgi.00221.2010)
60. Kohli R, Bradley D, Setchell KD, Eagon JC, Abumrad N & Klein S 2013a Weight loss induced by Roux-en-Y gastric bypass but not laparoscopic adjustable gastric banding increases circulating bile acids. Journal of Clinical Endocrinology and Metabolism 98 E708-E712. (doi:10.1210/jc.2012-3736)
61. Kohli R, Setchell KD, Kirby M, Myronovych A, Ryan KK, Ibrahim SH, Berger J, Smith K, Toure M, Woods SC et al. 2013b A surgical model in male obese rats uncovers protective effects of bile acids post-bariatric surgery. Endocrinology 154 2341-2351. (doi:10.1210/en.2012-2069)
62. Kumar DP, Rajagopal S, Mahavadi S, Mirshahi F, Grider JR, Murthy KS & Sanyal AJ 2012 Activation of transmembrane bile acid receptor TGR5 stimulates insulin secretion in pancreatic b cells. Biochemical and Biophysical Research Communications 427 600-605. (doi:10.1016/j.bbrc. 2012.09.104)
63. Le Chatelier E, Nielsen T, Qin J, Prifti E, Hildebrand F, Falony G, AlmeidaM, Arumugam M, Batto JM, Kennedy S et al. 2013 Richness of human gut microbiome correlates with metabolic markers. Nature 500 541-546. (doi:10.1038/nature12506)
64. LenicekM, Duricova D, Komarek V, Gabrysova B, Lukas M, Smerhovsky Z & Vitek L 2011 Bile acid malabsorption in inflammatory bowel disease: assessment by serum markers. Inflammatory Bowel Diseases 17 1322-1327. (doi:10.1002/ibd.21502)
65. Li X 2013 SIRT1 and energymetabolism. Acta Biochimica et Biophysica Sinica 45 51-60. (doi:10.1093/abbs/gms108)
66. Li T & Chiang JY 2014 Bile acid signaling in metabolic disease and drug therapy. Pharmacological Review 66 948-983. (doi:10.1124/pr.113.008201)
67. Li JV, Ashrafian H, Bueter M, Kinross J, Sands C, le Roux CW, Bloom SR, Darzi A, Athanasiou T, Marchesi JR et al. 2011 Metabolic surgery profoundly influences gut microbial-host metabolic cross-talk. Gut 60 1214-1223. (doi:10.1136/gut.2010.234708)
68. Li F, Jiang C, Krausz KW, Li Y, Albert I, Hao H, Fabre KM, Mitchell JB, Patterson AD & Gonzalez FJ 2013 Microbiome remodelling leads to inhibition of intestinal farnesoid X receptor signalling and decreased obesity. Nature Communications 4 2384. (doi:10.1038/ncomms3384)
69. de Luis DA, Duenas A, Martin J, Abad L, Cuellar L & Aller R 2002 Light symptoms following a high-dose intentional L-thyroxine ingestion treated with cholestyramine. Hormone Research 57 61-63. (doi:10.1159/000057950)
70. Maglich JM, Watson J, McMillen PJ, Goodwin B, Willson TM & Moore JT 2004 The nuclear receptor CAR is a regulator of thyroid hormone metabolism during caloric restriction. Journal of Biochemical Chemistry 279 19832-19838. (doi:10.1074/jbc.M313601200)
71. Maglich JM, Lobe DC & Moore JT 2009 The nuclear receptor CAR (NR1I3) regulates serum triglyceride levels under conditions of metabolic stress. Journal of Lipid Research 50 439-445. (doi:10.1194/jlr. M800226-JLR200)
72. Malisova L, Kovacova Z, Koc M, Kracmerova J, Stich V & Rossmeislova L 2013 Ursodeoxycholic acid but not tauroursodeoxycholic acid inhibits proliferation and differentiation of human subcutaneous adipocytes. PLoS ONE 8 e82086. (doi:10.1371/journal.pone.0082086)
73. Martin JH, Deacon CF, Gorrell MD & Prins JB 2011 Incretin-based therapies-review of the physiology, pharmacology and emerging clinical experience. Internal Medicine Journal 41 299-307. (doi:10.1111/j.1445-5994.2011.02439.x)
74. Mathew S, Lund RJ, Chaudhary LR, Geurs T & Hruska KA 2008 Vitamin D receptor activators can protect against vascular calcification. Journal of the American Society of Nephrology 19 1509-1519. (doi:10.1681/ASN. 2007080902)
75. Mazuy C, Helleboid A, Staels B & Lefebvre P 2015 Nuclear bile acid signaling through the farnesoid X receptor. Cellular and Molecular Life Sciences 72 1631-1650. (doi:10.1007/s00018-014-1805-y)
76. McGarr SE, Ridlon JM & Hylemon PB 2005 Diet, anaerobic bacterial metabolism, and colon cancer: a review of the literature. Journal of Clinical Gastroenterology 39 98-109.
77. Modica S, Gadaleta RM & Moschetta A 2010 Deciphering the nuclear bile acid receptor FXR paradigm. Nuclear Receptor Signaling 8 e005. (doi:10.1621/nrs.08005)
78. Mudaliar S, Henry RR, Sanyal AJ, Morrow L, Marschall HU, Kipnes M, Adorini L, Sciacca CI, Clopton P, Castelloe E et al. 2013 Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease. Gastroenterology 145 574-582. (doi:10.1053/j.gastro.2013.05.042)
79. Musri MM, Carmona MC, Hanzu FA, Kaliman P, Gomis R & ParrizasM2010 Histone demethylase LSD1 regulates adipogenesis. Journal of Biochemical Chemistry 285 30034-30041. (doi:10.1074/jbc.M110.151209)
80. Myronovych A, Kirby M, Ryan KK, Zhang W, Jha P, Setchell KD, Dexheimer PJ, Aronow B, Seeley RJ & Kohli R 2014 Vertical sleeve gastrectomy reduces hepatic steatosis while increasing serum bile acids in a weight-loss-independent manner. Obesity 22 390-400. (doi:10.1002/oby.20548)
81. Nauck MA, Vardarli I, Deacon CF, Holst JJ & Meier JJ 2011 Secretion of glucagon-like peptide-1 (GLP-1) in type 2 diabetes: what is up, what is down? Diabetologia 54 10-18. (doi:10.1007/s00125-010-1896-4)
82. Neish AS 2009 Microbes in gastrointestinal health and disease. Gastroenterology 136 65-80. (doi:10.1053/j.gastro.2008.10.080)
83. Neuschwander-Tetri BA, Loomba R, Sanyal AJ, Lavine JE, Van Natta ML, Abdelmalek MF, Chalasani N, Dasarathy S, Diehl AM, Hameed B et al. 2015 Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. Lancet 385 956-965. (doi:10.1016/S0140-6736(14)61933-4)
84. O'Brien PE 2010 Bariatric surgery: mechanisms, indications and outcomes. Journal of Gastroenterology and Hepatology 25 1358-1365. (doi:10.1111/j.1440-1746.2010.06391.x)
85. Ockenga J, Valentini L, Schuetz T, Wohlgemuth F, Glaeser S, Omar A, Kasim E, duPlessis D, Featherstone K, Davis JR et al. 2012 Plasma bile acids are associated with energy expenditure and thyroid function in humans. Journal of Clinical Endocrinology and Metabolism 97 535-542. (doi:10.1210/jc.2011-2329)
86. Park JS, Seo JH & Youn HS 2013 Gut microbiota and clinical disease: obesity and nonalcoholic Fatty liver disease. Pediatric Gastroenterology, Hepatology and Nutrition 16 22-27. (doi:10.5223/pghn.2013.16.1.22)
87. Parker HE, Wallis K, le Roux CW, Wong KY, Reimann F & Gribble FM 2012 Molecular mechanisms underlying bile acid-stimulated glucagon-like peptide-1 secretion. British Journal of Pharmacology 165 414-423. (doi:10.1111/j.1476-5381.2011.01561.x)
88. Parlesak A, Schaeckeler S, Moser L & Bode C 2007 Conjugated primary bile salts reduce permeability of endotoxin through intestinal epithelial cells and synergize with phosphatidylcholine in suppression of inflammatory cytokine production. Critical Care Medicine 35 2367-2374. (doi:10.1097/01.CCM.0000284586.84952.FB)
89. Patti ME, Houten SM, Bianco AC, Bernier R, Larsen PR, Holst JJ, Badman MK, Maratos-Flier E, Mun EC, Pihlajamaki J et al. 2009 Serum bile acids are higher in humans with prior gastric bypass: potential contribution to improved glucose and lipid metabolism. Obesity 17 1671-1677. (doi:10.1038/oby.2009.102)
90. Penney NC, Kinross J, Newton RC & Purkayastha S 2015 The role of bile acids in reducing the metabolic complications of obesity after bariatric surgery: a systematic review. International Journal of Obesity 39 1565-1574. (doi:10.1038/ijo.2015.115)
91. Perino A, Pols TW, Nomura M, Stein S, Pellicciari R & Schoonjans K 2014 TGR5 reduces macrophage migration through mTOR-induced C/EBPb differential translation. Journal of Clinical Invesigation 124 5424-5436. (doi:10.1172/JCI76289)
92. Pories WJ 2008 Bariatric surgery: risks and rewards. Journal of Clinical Endocrinology and Metabolism 93 S89-S96. (doi:10.1210/jc.2008-1641)
93. Potthoff MJ, Kliewer SA & Mangelsdorf DJ 2012 Endocrine fibroblast growth factors 15/19 and 21: from feast to famine. Genes and Development 26 312-324. (doi:10.1101/gad.184788.111)
94. Pournaras DJ, Glicksman C, Vincent RP, Kuganolipava S, Alaghband-Zadeh J, Mahon D, Bekker JH, Ghatei MA, Bloom SR, Walters JR et al. 2012 The role of bile after Roux-en-Y gastric bypass in promoting weight loss and improving glycaemic control. Endocrinology 153 3613-3619. (doi:10.1210/en.2011-2145)
95. Qi Y, Jiang C, Cheng J, Krausz KW, Li T, Ferrell JM, Gonzalez FJ & Chiang JY 2015 Bile acid signaling in lipid metabolism: metabolomic and lipidomic analysis of lipid and bile acid markers linked to anti-obesity and anti-diabetes in mice. Biochimica Biophysica Acta 1851 19-29. (doi:10.1016/j.bbalip.2014.04.008)
96. Qiao L, Studer E, Leach K, McKinstry R, Gupta S, Decker R, Kukreja R, Valerie K, Nagarkatti P, El Deiry W et al. 2001 Deoxycholic acid (DCA) causes ligand-independent activation of epidermal growth factor receptor (EGFR) and FAS receptor in primary hepatocytes: Inhibition of EGFR/mitogen-activated protein kinase-signaling module enhances DCA-induced apoptosis. Molecular Biology of the Cell 12 2629-2645. (doi:10.1091/mbc.12.9.2629)
97. Raufman JP, Cheng K & Zimniak P 2003 Activation of muscarinic receptor signaling by bile acids: physiological and medical implications. Digestive Diseases and Sciences 48 1431-1444. (doi:10.1023/A:1024733500950)
98. Ren K, Tang ZL, Jiang Y, Tan YM & Yi GH 2015 Apolipoprotein M. Clinical Chemica Acta 446 21-29. (doi:10.1016/j.cca.2015.03.038)
99. Renga B, Mencarelli A, Vavassori P, Brancaleone V & Fiorucci S 2010 The bile acid sensor FXR regulates insulin transcription and secretion. Biochimica Biophysica Acta 1802 363-372. (doi:10.1016/j.bbadis.2010. 01.002)
100. Renga B, Mencarelli A, Cipriani S, D'Amore C, Carino A, Bruno A, Francisci D, Zampella A, Distrutti E & Fiorucci S 2013 The bile acid sensor FXR is required for immune-regulatory activities of TLR-9 in intestinal inflammation. PLoS ONE 8 e54472. (doi:10.1371/journal. pone.0054472)
101. Ridlon JM, Kang DJ, Hylemon PB & Bajaj JS 2014 Bile acids and the gut microbiome. Current Opinion in Gastroenterology 30 332-338. (doi:10.1097/MOG.0000000000000057)
102. Rudling M, Camilleri M, Graffner H, Holst JJ & Rikner L 2015 Specific inhibition of bile acid transport alters plasma lipids and GLP-1. BMC Cardiovascular Disorders 15 75. (doi:10.1186/s12872-015-0070-9)
103. Ryan KK, Tremaroli V, Clemmensen C, Kovatcheva-Datchary P, Myronovych A, Karns R, Wilson-Perez HE, Sandoval DA, Kohli R, Backhed F et al. 2014 FXR is a molecular target for the effects of vertical sleeve gastrectomy. Nature 509 183-188. (doi:10.1038/nature13135)
104. Salmoirago-Blotcher E, Crawford S, Jackson E, Ockene J & Ockene I 2011 Constipation and risk of cardiovascular disease among postmenopausal women. American Journal of Medicine 124 714-723. (doi:10.1016/j. amjmed.2011.03.026)
105. Sayin SI, Wahlstrom A, Felin J, Jantti S, Marschall HU, Bamberg K, Angelin B, Hyotylainen T, Oresic M & Backhed F 2013 Gut microbiota regulates bile acid metabolism by reducing the levels of tauro-b-muricholic acid, a naturally occurring FXR antagonist. Cell Metabolism 17 225-235. (doi:10.1016/j.cmet.2013.01.003)
106. Schittenhelm B, Wagner R, Kahny V, Peter A, Krippeit-Drews P, Dufer M & Drews G 2015 Role of FXR in b-cells of lean and obese mice. Endocrinology 156 1263-1271. (doi:10.1210/en.2014-1751)
107. Sebastian-Ochoa A, Quesada-Charneco M, Fernandez-Garcia D, Reyes-Garcia R, Rozas-Moreno P & Escobar-Jimenez F 2008 Dramatic response to cholestyramine in a patient with Graves' disease resistant to conventional therapy. Thyroid 18 1115-1117. (doi:10.1089/thy. 2008.0094)
108. Seok S, Kanamaluru D, Xiao Z, Ryerson D, Choi SE, Suino-Powell K, Xu HE, Veenstra TD & Kemper JK 2013 Bile acid signal-induced phosphorylation of small heterodimer partner by protein kinase Cz is critical for epigenomic regulation of liver metabolic genes. Journal of Biochemical Chemistry 288 23252-23263. (doi:10.1074/jbc.M113.452037)
109. Seyer P, Vallois D, Poitry-Yamate C, Schutz F, Metref S, Tarussio D, Maechler P, Staels B, Lanz B, Grueter R et al. 2013 Hepatic glucose sensing is required to preserve β cell glucose competence. Journal of Clinical Invesigation 123 1662-1676. (doi:10.1172/JCI65538)
110. Shakir KM, Michaels RD, Hays JH & Potter BB 1993 The use of bile acid sequestrants to lower serum thyroid hormones in iatrogenic hyperthyroidism. Annals of Internal Medicine 118 112-113. (doi:10.7326/0003-4819-118-2-199301150-00006)
111. Shakir YA, Samsioe G, Khatibi EA, Nyberg P, Lidfeldt J, Agardh CD & Nerbrand C 2007 Health hazards in middle-aged women with cardiovascular disease: a case-control study of swedish women. The women's health in the Lund area (WHILA) study. Journal of Women's Health 16 406-414. (doi:10.1089/jwh.2006.0056)
112. Shen H, Zhang Y, Ding H, Wang X, Chen L, Jiang H & Shen X 2008 Farnesoid X receptor induces GLUT4 expression through FXR response element in the GLUT4 promoter. Cellular Physiology and Biochemistry 22 1-14. (doi:10.1159/000149779)
113. da-SilvaWS, Ribich S, Arrojo e Drigo R, CastilloM, PattiME&BiancoAC2011 The chemical chaperones tauroursodeoxycholic and 4-phenylbutyric acid accelerate thyroid hormone activation and energy expenditure. FEBS Letter 585 539-544. (doi:10.1016/j.febslet.2010.12.044)
114. Sipka S & Bruckner G 2014 The immunomodulatory role of bile acids. International Archives of Allergy and Immunology 165 1-8. (doi:10.1159/000366100)
115. Smith Z, Ryerson D & Kemper JK 2013 Epigenomic regulation of bile acid metabolism: emerging role of transcriptional cofactors. Molecular Cell Endocrinology 368 59-70. (doi:10.1016/j.mce.2012.04.008)
116. Song Y, Xu C, Shao S, Liu J, XingW, Xu J, Qin C, Li C, Hu B, Yi S et al. 2015 Thyroid-stimulating hormone regulates hepatic bile acid homeostasis via SREBP-2/HNF-4a/CYP7A1 axis. Journal of Hepatology 62 1171-1179. (doi:10.1016/j.jhep.2014.12.006)
117. Staels B & Kuipers F 2007 Bile acid sequestrants and the treatment of type 2 diabetes mellitus. Drugs 67 1383-1392. (doi:10.2165/00003495-200767100-00001)
118. Suzuki T, Oba K, Futami-Suda S, Suzuki K, Ouchi M, Igari Y, Matsumura N, Watanabe K, Kigawa Y & Nakano H 2007a Effects of colestimide on blood glucose-lowering activity and body weight in patients with type 2 diabetes and hypercholesterolemia. Journal of Nippon Medical School 74 81-84. (doi:10.1272/jnms.74.81)
119. Suzuki T, Oba K, Igari Y, Matsumura N, Watanabe K, Futami-Suda S, Yasuoka H, Ouchi M, Suzuki K, Kigawa Y et al. 2007b Colestimide lowers plasma glucose levels and increases plasma glucagon-like peptide-1 (7-36) levels in patients with type 2 diabetes mellitus complicated by hypercholesterolemia. Journal of Nippon Medical School 74 338-343. (doi:10.1272/jnms.74.338)
120. Talley NJ, Jones M, Nuyts G & Dubois D 2003 Risk factors for chronic constipation based on a general practice sample. American Journal of Gastroenterology 98 1107-1111. (doi:10.1111/j.1572-0241.2003.07465.x)
121. Thomas C, Gioiello A, Noriega L, Strehle A, Oury J, Rizzo G, Macchiarulo A, Yamamoto H, Mataki C, Pruzanski M et al. 2009 TGR5-mediated bile acid sensing controls glucose homeostasis. Cell Metabolism 10 167-177. (doi:10.1016/j.cmet.2009.08.001)
122. Tilg H & Moschen AR 2014 Microbiota and diabetes: an evolving relationship. Gut 63 1513-1521. (doi:10.1136/gutjnl-2014-306928)
123. Tomlinson E, Fu L, John L, Hultgren B, Huang X, Renz M, Stephan JP, Tsai SP, Powell-Braxton L, French D et al. 2002 Transgenic mice expressing human fibroblast growth factor-19 display increased metabolic rate and decreased adiposity. Endocrinology 143 1741-1747. (doi:10.1210/endo.143.5.8850)
124. Turnbaugh PJ, Ley RE, Mahowald MA, Magrini V, Mardis ER & Gordon JI 2006 An obesity-associated gut microbiome with increased capacity for energy harvest. Nature 444 1027-1031. (doi:10.1038/nature05414)
125. Vavassori P, Mencarelli A, Renga B, Distrutti E & Fiorucci S 2009 The bile acid receptor FXR is a modulator of intestinal innate immunity. Journal of Immunology 183 6251-6261. (doi:10.4049/jimmunol. 0803978)
126. Vinik AI, Maser RE, Mitchell BD & Freeman R 2003 Diabetic autonomic neuropathy. Diabetes Care 26 1553-1579. (doi:10.2337/diacare.26. 5.1553)
127. Vítek L 2015 Bile acid malabsorption in inflammatory bowel disease. Inflammatory Bowel Diseases 21 476-483. (doi:10.1097/MIB. 0000000000000193)
128. Vrieze A, Schopman JE, Admiraal WM, Soeters MR, Nieuwdorp M, Verberne HJ & Holleman F 2012 Fasting and postprandial activity of brown adipose tissue in healthy men. Journal of Nuclear Medicine 53 1407-1410. (doi:10.2967/jnumed.111.100701)
129. Wang X, Fang X, Zhou J, Chen Z, Zhao B, Xiao L, Liu A, Li YS, Shyy JY, Guan Y et al. 2013 Shear stress activation of nuclear receptor PXR in endothelial detoxification. PNAS 110 13174-13179. (doi:10.1073/pnas. 1312065110)
130. Wang S, Lei T, Zhang K, Zhao W, Fang L, Lai B, Han J, Xiao L & Wang N 2014 Xenobiotic pregnane X receptor (PXR) regulates innate immunity via activation of NLRP3 inflammasome in vascular endothelial cells. Journal of Biochemical Chemistry 289 30075-30081. (doi:10.1074/jbc. M114.578781)
131. Watanabe M, Houten SM, Mataki C, Christoffolete MA, Kim BW, Sato H, Messaddeq N, Harney JW, Ezaki O, Kodama T et al. 2006 Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation. Nature 439 484-489. (doi:10.1038/nature04330)
132. Wu W, Liu X, Peng X, Xue R, Ji L, Shen X, Chen S, Gu J & Zhang S 2014 Bile acids override steatosis in farnesoid X receptor deficient mice in a model of non-alcoholic steatohepatitis. Biochemical and Biophysical Research Communications 448 50-55. (doi:10.1016/j.bbrc.2014.04.048)
133. Yang TT, Chang CK, Tsao CW, Hsu YM, Hsu CT & Cheng JT 2009 Activation of muscarinic M-3 receptor may decrease glucose uptake and lipolysis in adipose tissue of rats. Neuroscience Letter 451 57-59. (doi:10.1016/j.neulet.2008.12.029)
134. Yang Y, Hwang S, KimM, Lim Y, Kim MH, Lee S, Lim DJ, KangMI & Cha BY 2015 Refractory Graves' disease successfully cured by adjunctive cholestyramine and subsequent total thyroidectomy. Endocrinology and Metabolism [in press].
135. Yusta B, Holland D, Waschek JA & Drucker DJ 2012 Intestinotrophic glucagon-like peptide-2 (GLP-2) activates intestinal gene expression and growth factor-dependent pathways independent of the vasoactive intestinal peptide gene in mice. Endocrinology 153 2623-2632. (doi:10.1210/en.2012-1069)
136. Zhang J, Huang W, Qatanani M, Evans RM & Moore DD 2004 The constitutive androstane receptor and pregnane X receptor function coordinately to prevent bile acid-induced hepatotoxicity. Journal of Biochemical Chemistry 279 49517-49522. (doi:10.1074/jbc. M409041200)
137. Zhang Y, Lee FY, Barrera G, Lee H, Vales C, Gonzalez FJ, Willson TM & Edwards PA 2006 Activation of the nuclear receptor FXR improves hyperglycemia and hyperlipidemia in diabetic mice. PNAS 103 1006-1011. (doi:10.1073/pnas.0506982103)
138. Zhang H, DiBaise JK, Zuccolo A, Kudrna D, Braidotti M, Yu Y, Parameswaran P, Crowell MD, Wing R, Rittmann BE et al. 2009 Human gut microbiota in obesity and after gastric bypass. PNAS 106 2365-2370. (doi:10.1073/pnas.0812600106)
139. Zhou H & Hylemon PB 2014 Bile acids are nutrient signaling hormones. Steroids 86C 62-68. (doi:10.1016/j.steroids.2014.04.016)
140. Zhou JH, Pan ZY, Zhang YF, Cui WY, Long CL &Wang H 2014 Stimulation of endothelial non-neuronal muscarinic receptor attenuates the progression of atherosclerosis via inhibiting endothelial cells activation. Zhongguo Ying Yong Sheng Li Xue Za Zhi 30 549-559.
141. Zwicker BL & Agellon LB 2013 Transport and biological activities of bile acids. International Journal of Biochemistry & Cell Biology 45 1389-1398. (doi:10.1016/j.biocel.2013.04.012)